Aakash Desai

Aakash Desai: Efficacy, Innovation and Cost of FDA-Approved NSCLC Drugs

Aakash Desai, Assistant Professor at O’Neal Comprehensive Cancer Center at UAB, shared on LinkedIn:

“We’re excited to share our poster from ESMO24 on the ‘Efficacy, Innovation and Cost of FDA-Approved NSCLC Drugs’, co-authored with Daniel Michaeli and team.

Key Insights:

  • 64% of FDA-approved drugs for NSCLC have biomarker-based targets like EGFR, ALK, and PD-L1.
  •  The average time from IND to FDA approval is 1.8 years shorter for NSCLC drugs.
  • Drugs with biomarkers demonstrated significantly greater overall survival (OS) and progression-free survival (PFS).
  • Median monthly cost for NSCLC treatments is $18,822, with biomarker-based therapies often priced higher.

These findings highlight the balance between innovation and cost in lung cancer treatment. Let’s continue working towards more effective and accessible options for patients!”

Aakash Desai

Source: Aakash Desai/LinkedIn

Aakash Desai cancer Daniel Michaeli ESMO ESMO24 FDA FDA approval Lung cancer lung cancer treatment NSCLC NSCLC drugs OncoDaily Oncology patient care